New biomarker study reveals progress in predicting AD dementia

A validated model combining plasma phospho-tau (p-tau) with other measures has been shown to have high accuracy in predicting the 4-year risk of progression to Alzheimer’s disease (AD) dementia in people with subjective cognitive decline (SCD) or mild cognitive impairment (MCI).

The combination model, available as an app (PredictAD) for research purposes, is currently being assessed further in a large primary care-based AD detection study.